Article

Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study

Sofía Ruiz-Medina 1, Silvia Gil 1, Begoña Jimenez 1, Pablo Rodriguez-Brazzarola 2, Tamara Diaz-Redondo 1, Mireya Cazorla 1, Marta Muñoz-Ayllon 1, Inmaculada Ramos 1, Carmen Reyna 1, María José Bermejo 1, Ana Godoy 1, Esperanza Torres 1, Manuel Cobo 1, Laura Galvez 1, Antonio Rueda 1, Emilio Alba 1 and Nuria Ribelles 1,*

1 Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, 29010 Málaga, Spain; sofia.ruizmedina@gmail.com (S.R.-M.); silviagilcalle@yahoo.es (S.G.); begojrodri@google.com (B.J.); tdredondo@gmail.com (T.D.-R.); mirecalo@hotmail.com (M.C.); aylion.m@gmail.com (M.M.-A.); ramosgarcia22@gmail.com (I.R.); c.reyna.fortes@gmail.com (C.R.); cheberpe@gmail.com (M.J.B.); anagodorton@gmail.com (A.G.); esp_torres2001@yahoo.es (E.T.); manuecobodolat@yahoo.es (M.C.); lauragalvezcarvajal@hotmail.com (L.G.); antonio.rueda.dominguez@juntadeandalucia.es (A.R.); ealbac@uma.es (E.A.)
2 Grupo de Inteligencia Computacional en Biomedicina, ETSI Ingeniería Informática, Universidad de Málaga, 29010 Málaga, Spain; pabrod@uma.es
* Correspondence: nuria.ribelles.ssps@juntadeandalucia.es; Tel.: +34-951-03-21-91

Citation: Ruiz-Medina, S.; Gil, S.; Jimenez, B.; Rodriguez-Brazzarola, P.; Diaz-Redondo, T.; Cazorla, M.; Muñoz-Ayllon, M.; Ramos, I.; Reyna, C.; Bermejo, M.J.; et al. Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study. Cancers 2021, 13, 3215. https://doi.org/10.3390/cancers13133215

Abstract: The COVID-19 pandemic has caused a profound change in health organizations at both the primary and hospital care levels. This cross-sectional study aims to investigate the impact of the COVID-19 pandemic in the annual rate of new cancer diagnosis in two university-affiliated hospitals. This study includes all the patients with a pathological diagnosis of cancer attended in two hospitals and neck tumors (2907 patients in 2019 which represented a decrease of 17.2% (p = 0.0001). Differences in the number of patients diagnosed between 2018 and 2019 or between 2017 and 2019, so that loss of cancer patients could be attributed to changes made in health systems due to the pandemic. The delay in the diagnosis may have important consequences in the prognosis of cancer patients, so health systems should carry out an effort similar to that made with the pandemic to recover all lost patients who have remained undiagnosed.

Keywords: cancer diagnoses; COVID-19 pandemic; real data
1. Introduction

There is no doubt that the COVID-19 pandemic has transformed healthcare like no other emergency has done before. In a short time, it has been necessary to allocate the use of a large part of the health services resources to the care of COVID-19 patients, which has had a notorious impact on the management of other diseases.

Changes have occurred at all levels of care, with data indicating a 30% decrease in primary care consultations, of which more than half have been carried out in a remote mode [1], and the temporary closure of >60% of hospital outpatient radiology facilities [2]. In addition, another factor to consider in the delay of the screening, diagnosis, or treatment of non-COVID-19 diseases has been the patients themselves, because they have deferred or suspended visits to health facilities for fear of contracting the coronavirus [3–5].

Cancer patients have also been affected by the decrease in health resources designated to their management. The authorities of several countries gave instructions to temporarily suspend breast, colorectal, and cervical cancer screening programs [6,7]. Medicare data show that screening procedures for breast, colon, prostate, and lung cancer were lower in March–July 2020 compared to March–July 2019, with a maximum decrease in April of 85%, 75%, 74% and 56%, respectively [8]. Breast and colorectal screening encounters declined by 89.2% and 84.5%, respectively, between January and April 2020 compared to the same period in 2019, according to data from the TriNetX platform [9].

A decrease in the number of new diagnosed cancer cases has been reported by authors from several countries. Data from US patients showed that during March-April 2020, the weekly number of newly identified patients with breast, colorectal, lung, pancreatic, gastric, or esophageal cancer decreased by 46.4% compared to January 2019-February 2020 [10]. In the Netherlands, the number of new weekly cases dropped by 26% in April compared to January 2020 [6]. Also, a decline of 44.9% in weeks 11 to 20 of 2020 compared to 2018 to 2019 was found in Italy [11] and the number of new cancer diagnoses fell by 30% in April 2020 compared to April 2019 in Germany [12]. Furthermore, a significant increase in the incidence of more advanced stages of melanoma [13], breast [14,15] and lung cancer cases [16] at diagnosis has been observed.

Likewise, cancer treatments have been affected by the pandemic. According to data from the National Health Service (NHS), in England, there was a relative reduction of 22% in the number of diagnosed cases of colorectal cancer that were included in the 31-day-to treatment pathway, and of 31% in the number of colorectal cancer operations in April 2020 compared with 2019 [17]. In the same period, the number of radiotherapy courses delivered across the English NHS fell by 20% [18]. Between March to July 2020, a decrease in the billing frequency for chemotherapy administration was observed in comparison to 2019, with a maximum of 32% in July, according to Medicare data [8]. Data from a multicenter nationwide study from Spain that collected information from departments treating oncology patients through an electronic questionnaire, reported a decrease of 20.3% in the number of new patients’ referrals and of 14.3% in the mean number of patients visiting day hospitals between March–June 2020 compared to March–June 2019 [19].

Undeniably, all the changes mentioned above may have consequences on the outcome of cancer patients, and several estimates have been made in this regard. Using data from the lockdown period, it has been predicted that a 3-month delay in diagnoses will result in a 15–18% reduction in the 10-year net survival for bladder, brain, head and neck, liver, lung, esophagus, ovary, and stomach cancer [20]. Compared to pre-pandemic data, an estimated 7.9–9.6% increase in the number of deaths due to breast cancer up to year 5 after diagnosis was determined. The increase is 15.3–16.6% for colorectal cancer, 4.8–5.3% for lung cancer, and 5.8–6% for esophageal cancer [21]. Modeling the effect of COVID-19 on cancer screening and treatment for breast and colorectal cancer in a US scenario, almost 10,000 excess deaths are expected over the next decade [3].

The information published to date offers estimates or partial data regarding the effect of the pandemic on the incidence rates of new cases of cancer, providing results only for the first months of the pandemic. The purpose of this study is to evaluate the real
changes, without estimates, in the rate of cancer diagnosis during the first full year since the declaration of the lockdown in a population area of approximately one and a half million inhabitants. This study also includes all types of neoplasms.

2. Materials and Methods

This cross-sectional study involved all patients with a pathological diagnosis of cancer who had at least one encounter in two university-affiliated hospitals in Málaga (Spain, Hospital Regional and Hospital Virgen de la Victoria) during the first year of the pandemic. Between the two hospitals, an area of 1,500,000 people is attended, representing 80% of the total province’s population. All patients with at least one encounter in either of the two hospitals are always registered in our own information system. This system is called Galen and is comprised of a database of patients and their electronic health records, among other utilities, and includes data on more than 49,000 patients and nearly 54,000 neoplasms [22].

In Spain, the state of national emergency was declared as a result of COVID-19 on 13 March 2020. Thus, the study population considered all patients diagnosed between 13 March 2020 and 13 March 2021, and the reference population considered those cases diagnosed between 13 March 2019 and 13 March 2020, including all tumor sites. The date of the pathological report was taken as the diagnosis date. In order to clarify whether the differences found in the incidence rates between the study population and the reference group were due to the pandemic or to unrelated variations, the patients diagnosed in the same periods in the years 2018 and 2017 were also compared with the reference population. If significant differences were identified in the total incidence rate between 2020 and 2019, but no significant differences were observed between 2018 and 2019 and between 2017 and 2019, the hypothesis that the COVID-19 pandemic has significantly impaired the process of diagnosing cancer patients would be supported. Month 1 of the analysis was considered to elapse between March 13 and April 12 of the corresponding year and so on until month 12, which was considered to elapse between February 13 and March 12 of the following year. The number of COVID-19 cases diagnosed monthly in the province of Málaga was also considered when analyzing the evolution in the incidence of new cancer cases during the first year of the pandemic [23].

In addition, this study also analyzed whether there were changes in the distribution of stages of neoplasms at diagnosis in the different populations included. For this purpose, stages I-II were grouped as early stage and III-IV as advanced stage. Patients with an unknown stage were excluded for this second analysis.

Although the analysis of this study is retrospective, all the data used have been collected prospectively. The numbers of new diagnosed cancer cases in the different time periods evaluated were compared using the Wilcoxon test for paired samples. The Fisher test was used to analyze the possible differences in the distribution of stages at diagnosis between the distinct study periods. All statistical analysis was carried out using R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria), assuming a p value of 0.05.

3. Results

During 2020, there were 2340 new patients diagnosed with cancer compared to 2825 in 2019, with similar median age and gender distribution in both populations (Table 1). The neoplasms with the highest incidence rates were breast, lung, colorectal, hematological, head and neck, and pancreas (Table 2). In absolute terms, 485 fewer patients were diagnosed in 2020 than in 2019, which represents a statistically significant decrease of −17.2% (p = 0.0001). The neoplasms with the greatest relative declines, between −47.1% and −32.4%, were CNS, kidney, prostate, mesothelioma, and gallbladder and bile duct tumors (Table 2).
Table 1. Patients’ characteristics 2020 and 2019.

| Characteristic          | 2020   | 2019   |
|-------------------------|--------|--------|
| N                       | 2340   | 2825   |
| Age at diagnoses        |        |        |
| Median (range)          | 63 (14–96) | 64 (17–100) |
| Gender                  |        |        |
| Male                    | 1089   | 1324   |
| Female                  | 1251   | 1501   |
| Early Stage             |        |        |
| 0-I                     | 5      | 12     |
| I                       | 326    | 434    |
| II                      | 477    | 603    |
| TOTAL                   | 808    | 1049   |
| Advanced Stage          |        |        |
| III                     | 556    | 623    |
| IV                      | 855    | 939    |
| Total                   | 1378   | 1562   |
| Unknown Stage           | 154    | 214    |

In addition, it is necessary to highlight that, during 2020, 195 breast cancers (−26.1%), 82 colorectal neoplasms (−16.9%), or 24 head and neck tumors (−19.8%) were not diagnosed in comparison to 2019. However, the relative change in lung or pancreatic tumors was smaller, −5.9% and −1.1%, respectively, which meant that 29 less patients were diagnosed with lung cancer and only one less patient was diagnosed with pancreatic cancer.

Table 2. Neoplasms annual incidence and relative changes.

| Neoplasm                  | 2020   | 2019   | % Change |
|---------------------------|--------|--------|----------|
| Breast                    | 551    | 746    | −26.1%   |
| Lung                      | 463    | 492    | −5.9%    |
| Colorectal                | 402    | 484    | −16.9%   |
| Hematologic               | 108    | 86     | 25.6%    |
| Head and Neck             | 97     | 121    | −19.8%   |
| Pancreas                  | 90     | 91     | −1.1%    |
| Stomach                   | 71     | 77     | −7.8%    |
| Ovary                     | 71     | 69     | 2.9%     |
| Bladder                   | 58     | 70     | −17.1%   |
| Sarcoma                   | 54     | 73     | −26.0%   |
| Esophagus                 | 48     | 52     | −7.7%    |
| Gallbladder and bile duct | 41     | 61     | −32.8%   |
| Prostate                  | 39     | 61     | −36.1%   |
| Cervix                    | 38     | 46     | −17.4%   |
| Others                    | 35     | 64     | −45.3%   |
| Melanoma                  | 34     | 41     | −17.1%   |
| Germ cells                | 31     | 33     | −6.1%    |
| Endometrium               | 25     | 37     | −32.4%   |
| Kidney                    | 22     | 37     | −40.5%   |
| GIST                      | 19     | 15     | 26.7%    |
| CNS                       | 18     | 34     | −47.1%   |
| CUP                       | 17     | 23     | −26.1%   |
| Mesothelioma              | 8      | 12     | −33.3%   |
| TOTAL                     | 2340   | 2825   | −17.2%   |

\[ p = 0.0001. \text{CUP: Cancer of unknown primary site; GIST: Gastrointestinal stromal tumor; CNS: central nervous system.} \]

All types of neoplasms experienced a decrease in their incidence in 2020 compared to 2019, except for hematological tumors and, to a lesser extent, gastrointestinal stromal tumor (GIST) and ovarian tumors.
If we look at the changes observed in the monthly number of diagnoses between 2020 and 2019 (Figure 1) and we evaluate them in relation to the number of COVID-19 cases diagnosed monthly in the province of Málaga (Table S1), we can notice that, during the first month of the pandemic, there was a decrease of $-34.7\%$ in the number of diagnosed patients, which reached $-34.9\%$ and $-49.3\%$ in months 11 and 12 of the study, coinciding with the third wave after Christmas.

In 2018, 2840 new cases of cancer were diagnosed, and in 2017, there were 2909. As expected, the median age and the distribution by gender were similar for the two years and also for 2019 (Tables S2 and S3). The incident rate analysis did not show significant differences between 2018 and 2019 and between 2017 and 2019. There was an increase of 0.5% between 2018 and 2019 ($P = 0.96$). The increase was slightly higher between 2017 and 2019, reaching 3% ($P = 0.68$).

Table S4 detail the annual incidence of each type of neoplasia in 2018 and Table S5 the same data regarding 2017, as well as their relative variation with respect to 2019. In both study periods, only some of the types of neoplasms analyzed showed changes in their incidence.

The analysis of the monthly changes between 2018 and 2019 is shown in Supplementary Figure S1 and between 2017 and 2019 is presented in Supplementary Figure S2. As expected, changes are observed in the number of patients diagnosed according to the months, but the differences between the study periods never reach the magnitude of the greatest changes observed during the first year of the COVID-19 pandemic.

The analysis of the distribution by stages at diagnosis did not show significant differences between the number of early and advanced cases diagnosed in 2020 and 2019, nor in the other two study periods analyzed (Figure 2, Figures S3 and S4).
Figure 2. Comparison of early and advanced stages in the ten most frequent neoplasms between 2020 and 2019.

However, if we examine the data in detail, we can observe that there are some neoplasms, in which the percentage of advanced stages at diagnosis had remained relatively constant during the previous years (2019, 2018, and 2017), that, in 2020 showed an increase in the number of advanced cases. Thus, pancreatic cancer showed an increase of 8.7%, germ cells and head and neck tumors increased around 6%, and breast and colon neoplasms increased over 3% (Table 3, Tables S6 and S7).

Table 3. Annual distribution of tumor stages 2020–2019.

| NEOPLASIAS                     | Early 2020 | Early 2020 (%) | Early 2019 | Early 2019 (%) | Advanced 2020 | Advanced 2020 (%) | Advanced 2019 | Advanced 2019 (%) |
|--------------------------------|------------|----------------|------------|----------------|---------------|-------------------|---------------|-------------------|
| Breast                         | 410        | 76.6%          | 587        | 80.3%          | 125           | 23.4%             | 144           | 19.7%             |
| Lung                           | 65         | 14.2%          | 69         | 14.2%          | 392           | 85.8%             | 416           | 85.8%             |
| Colorectal                     | 100        | 25.5%          | 135        | 28.5%          | 292           | 74.5%             | 339           | 71.5%             |
| Hematologic                    | 38         | 40.4%          | 33         | 42.3%          | 56            | 59.6%             | 45            | 57.7%             |
| Head and neck                  | 10         | 10.9%          | 19         | 17.6%          | 82            | 89.1%             | 89            | 82.4%             |
| Pancreas                       | 14         | 17.5%          | 22         | 26.2%          | 66            | 82.5%             | 62            | 73.8%             |
| Ovary                          | 19         | 28.4%          | 18         | 29.5%          | 48            | 71.6%             | 43            | 70.5%             |
| Stomach                        | 15         | 22.7%          | 16         | 23.5%          | 51            | 77.3%             | 52            | 76.5%             |
| Bladder                        | 29         | 60.4%          | 31         | 50.0%          | 19            | 39.6%             | 31            | 50.0%             |
| Esophagus                      | 5          | 11.6%          | 9          | 20.0%          | 38            | 88.4%             | 36            | 80.0%             |
| Gallbladder and bile duct      | 7          | 17.9%          | 7          | 12.7%          | 32            | 82.1%             | 48            | 87.3%             |
| Cervix                         | 20         | 52.6%          | 22         | 48.9%          | 18            | 47.4%             | 23            | 51.1%             |
| Prostate                       | 5          | 14.3%          | 4          | 7.3%           | 30            | 85.7%             | 51            | 92.7%             |
| Melanoma                       | 15         | 46.9%          | 4          | 10.5%          | 17            | 53.1%             | 34            | 89.5%             |
| Sarcoma                        | 10         | 31.3%          | 16         | 44.4%          | 22            | 68.8%             | 20            | 55.6%             |
| Germ cells                     | 25         | 86.2%          | 25         | 92.6%          | 4             | 13.8%             | 2             | 7.4%              |
| Endometrium                    | 8          | 32.0%          | 11         | 30.6%          | 17            | 68.0%             | 25            | 69.4%             |
| Others                         | 6          | 24.0%          | 10         | 20.0%          | 19            | 76.0%             | 40            | 80.0%             |
| Kidney                         | 0          | 0.0%           | 5          | 14.3%          | 20            | 100.0%            | 30            | 85.7%             |
| CUP                            | 0          | 0.0%           | 0          | 0.0%           | 17            | 100.0%            | 23            | 100.0%            |
| GIST                           | 7          | 43.8%          | 6          | 60.0%          | 9             | 56.3%             | 4             | 40.0%             |
| Mesothelioma                   | 0          | 0.0%           | 0          | 0.0%           | 4             | 100.0%            | 7             | 100.0%            |

P = non-significant between stages at diagnosis 2020 vs 2019.
4. Discussion

The appearance of the COVID-19 pandemic has resulted in serious consequences for oncology, starting with the delay in diagnostic procedures. In the UK, 35% fewer diagnostic tests were performed between March and August 2020 compared to the same period in 2019 [24]. In North Carolina (USA), the monthly number of diagnostic mammography and breast biopsies was reduced to a maximum of −48.9% and −40.9%, respectively, after March 2020 [25]. The number of colonoscopies performed in England during April 2020 was 92% lower than for the same month in 2019 [17]. These changes in the number of diagnostic procedures routinely performed have necessarily led to a general decline in the number of patients diagnosed with cancer since the beginning of the pandemic. During March and April 2020, the mean number of weekly patients diagnosed with breast, colorectal, lung, pancreatic, or gastric cancer in the US decreased by 46.6% for these 6 types of cancer combined, with the greatest reduction for breast cancer (−51.8%) and the lowest for pancreatic cancer (−24.7%) [10]. Similar findings have been reported in the number of weekly patients diagnosed during the first four months of the pandemic in the Netherlands [6], Italy [11], Germany [12], Spain [19] or Australia [26].

Our results show a significant decrease in the total number of patients diagnosed during the entire first year after the pandemic compared to the previous year. Thus, in 2020, 2340 new cancer patients were diagnosed compared to 2825 in 2019; that is, 485 (−17.2%) potential cancer patients were still undiagnosed. Although the relative decrease in the number of cases was greater in some types of neoplasms, such as CNS, kidney, prostate, or mesothelioma, the findings observed for breast and colorectal cancer are more impressive. Certainly, although the percentage of relative change in 2020 compared to 2019 has been lower in breast and colorectal cancer, their total incidence in the population determines that the situation caused by the COVID-19 pandemic negatively affects a greater number of patients. In fact, both types of neoplasms are categories in which we have observed a greater number of patients that have not been diagnosed in 2020 compared to 2019: 195 patients for breast cancer and 82 for colon cancer. It should be noted that, in these two types of neoplasms, screening programs constitute a relevant procedure in their management, and perhaps this issue may have influenced the decline in their diagnoses. Although there is no data in this regard from Spain, in other countries such as UK [7,24], the Netherlands [6], Australia [26], US [9,25], or Italy [14], screening programs have been suspended during certain periods of the pandemic.

An obvious consequence of the delay in diagnosis is that patients will present a more advanced stage of the disease when they are finally diagnosed over the next few months, which will undoubtedly worsen their prognosis, but health systems will also be greatly affected since the treatment and management of advanced cancer is much more expensive than during the early stages. There are data that indicate that the pandemic has significantly influenced the increase in advanced stages at diagnosis in melanoma [13], breast [14,15], and lung cancer [16]. In our population, we have observed an increase in advanced cases of pancreatic, germ cell, head and neck cancer, and to a lesser extent, breast and colorectal cancer. This difference has not been statistically significant, which could be due to the sample size. This could also be because not enough time has elapsed for this difference to be evident. We believe that the distribution of disease stages will change in the coming months.

The main strength of our work is that, to our knowledge, this is the first published data on the effect of the COVID-19 pandemic on cancer diagnosis for a full year that also includes all tumor types [6,10–12]. It should be noted that our data and comparisons are real and not estimates, and that the monthly number of diagnosed COVID-19 cases have also been included in the analysis. However, a limitation of our study is that it does not include the entire population of the province of Málaga, as data from the other two small hospitals are not available. In addition, there are a number of private providers that deliver medical oncology whose data are not available. On the other hand, the data referring to a
tumor type as relevant, such as prostate neoplasms, are not assessable since the healthcare structure of its management has undergone changes in the last 3 years.

Our study shows that a significant number of cancer patients have not been diagnosed throughout 2020, and that they would have been diagnosed if the COVID-19 pandemic had not occurred. It is true that health systems have done what needed to be done to control the COVID-19 pandemic. But it is no less true that health systems must enable all the necessary resources to improve procedures for cancer patients in order to recover all lost patients who have remained undiagnosed, as well as to prevent new patients from encountering a similar situation of diagnostic delay.

5. Conclusions

During the first year of the COVID-19 pandemic there has been a significant decrease in the number of cancer patients diagnosed in our area, due not only to changes in primary and hospital care, but probably also due to the fear of the patients themselves to get COVID-19 infection. It will take a great effort from the health authorities to care for these lost patients while continuing with the usual workload from 2021 onwards.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13133215/s1, Figure S1: Comparative of monthly new diagnosis of all tumor sites between 2018 and 2019, Figure S2. Comparative of monthly new diagnosis of all tumor sites between 2017 and 2019, Figure S3. Comparison of early and advanced stages in the ten most frequent neoplasms between 2018 and 2019, Figure S4. Comparison of early and advanced stages in the ten most frequent neoplasms between 2017 and 2019, Table S1 Monthly number of COVID-19 cases in Málaga, Table S2 Patients’ characteristics 2018 and 2019, Table S3 Patients’ characteristics 2017 and 2019, Table S4 Neoplasms annual incidence and relative changes 2018 and 2019, Table S5 Neoplasms annual incidence and relative changes 2017 and 2019, Table S6 Annual distribution of tumor stages 2018 and 2019, Table S7 Annual distribution of tumor stages 2017 and 2019.

Author Contributions: N.R. and S.R.-M. designed the study; N.R., S.R.-M., S.G., B.J., T.D.-R., M.C. (Mireya Cazorla), M.M.-A., I.R., C.R., M.J.B., A.G., E.T., M.C. (Manuel Cobo), L.G., A.R. and E.A. acquired the data; N.R., P.R.-B., S.R.-M. performed the statistical analysis; N.R., P.R.-B., S.R.-M., A.R., E.A. analyzed and interpreted the data; N.R. and S.R.-M. drafted the manuscript, A.R. and E.A. corrected the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. All the patient data was analyzed in anonymized and aggregated form. Thus, ethical review and approval were waived for this study.

Informed Consent Statement: Patient data were analyzed in aggregated form and therefore obtaining informed consent was not considered necessary.

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Watt, T.; Firth, Z.; Fisher, R.; Thorlby, R.; Kelly, E. Use of Primary Care during the COVID-19 Pandemic. Patient-Level Data Analysis of the Impact of COVID-19 on Primary Care Activity in England. 2020. Available online: https://www.health.org.uk/news-and-comment/charts-and-infographics/use-of-primary-care-during-the-covid-19-pandemic (accessed on 24 April 2021).

2. Siegal, D.S.; Wessman, B.; Zadorozny, J.; Palazzolo, J.; Montana, A.; Rawson, J.V.; Norbash, A.; Brown, M.L. Operational Radiology Recovery in Academic Radiology Departments After the COVID-19 Pandemic: Moving Toward Normalcy. J. Am. Coll. Radiol. 2020, 17, 1101–1107. [CrossRef]

3. Sharpless, N.E. COVID-19 and cancer. Science 2020, 368, 1290. [CrossRef] [PubMed]

4. Barten, D.G.; Latten, G.H.; van Osch, F.H. Reduced Emergency Department Utilization During the Early Phase of the COVID-19 Pandemic: Viral Fear or Lockdown Effect? Disaster Med. Public Heal. Prep. 2020, 2020, 1–4. [CrossRef] [PubMed]
5. Vanni, G.; Materazzo, M.; Pellicciaro, M.; Ingallinella, S.; Rho, M.; Santori, F.; Corsetta, M.; Caspi, J.; Makarova, A.; Pistolese, C.A.; et al. Breast Cancer and COVID-19: The Effect of Fear on Patients’ Decision-making Process. In Vivo 2020, 34, 1651–1659. [CrossRef] [PubMed]

6. Dinmohamed, A.G.; Visser, O.; Verhoeven, R.H.A.; Louwman, M.W.J.; van Nederveen, F.H.; Willems, S.M.; Merkx, M.A.W.; Lemmens, V.E.P.; Nagtegaal, I.D.; Siesling, S. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020, 21, 750–751. [CrossRef]

7. Richards, M.; Anderson, M.; Carter, P.; Ebert, B.L.; Mossialos, E. The impact of the COVID-19 pandemic on cancer care. Nat. Rev. Cancer 2020, 1, 565–567. [CrossRef]

8. Patt, D.; Gordon, L.; Diaz, M.; Okon, T.; Grady, L.; Harmison, M.; Markward, N.; Sullivan, M.; Peng, J.; Zhou, A. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin. Cancer Inform. 2020, 4, 1059–1071. [CrossRef]

9. London, J.W.; Fazio-Eynullayeva, E.; Palchuk, M.B.; Sankey, P.; McNair, C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clin. Cancer Inform. 2020, 4, 657–665. [CrossRef]

10. Kaufman, H.W.; Chen, Z.; Nelson, J.; Pesko, Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. Jama Netw. Open 2020, 3, e2017267. [CrossRef]

11. Ferrara, G.; De Vincentiis, L.; Ambrosi-Spaltro, A.; Barbareschi, M.; Bertolini, V.; Contato, E.; Crivelli, F.; Faley, E.; Mariani, M.P.; Morelli, L.; et al. Cancer Diagnostic Delay in Northern and Central Italy During the 2020 Lockdown Due to the Coronavirus Disease 2019 Pandemic. Am. J. Clin. Pathol. 2021, 155, 64–68. [CrossRef]

12. Jacob, L.; Loosen, S.H.; Kalder, M.; Luedde, T.; Roderburg, C.; Kostev, K. Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany. Cancers 2021, 13, 408. [CrossRef] [PubMed]

13. Ricci, F.; Fania, L.; Paradiisi, A.; Di Lella, G.; Pallotta, S.; Sobrino, L.; Panebianco, A.; Abeni, D. Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J. Eur. Acad. Dermatol. Venereol. 2020, 34. [CrossRef] [PubMed]

14. Toss, A.; Isca, C.; Venturelli, M.; Nasso, C.; Ficarra, G.; Armocida, F.; Barbieri, E.; Cortesi, L.; Moscetti, L.; et al. Two-month stop in mammographic screening significantly affects breast cancer stage at diagnosis and upfront treatment in the COVID era. ESMO Open 2021, 6, 100055. [CrossRef]

15. Vanni, G.; Tazzioli, G.; Pellicciaro, M.; Materazzo, M.; Paolo, O.; Catadori, F.; Combi, F.; Papi, S.; Pistolese, C.A.; Cotesta, M.; et al. Cancer Diagnostic Delay in Northern and Central Italy During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients. Anticancer Res. 2020, 40, 7119–7125. [CrossRef] [PubMed]

16. Park, J.Y.; Lee, Y.J.; Kim, T.; Lee, C.Y.; Kim, H.I.; Kim, J.-H.; Park, S.H.; Kwang, Y.I.; Jung, K.-S.; Jung, S.H. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea. BMC Cancer 2020, 20, 1–8. [CrossRef]

17. Morris, E.J.A.; Goldacre, R.; Spata, E.; Maffum, M.; Finan, P.; Shelton, J.; Richards, M.; Spencer, K.; Emson, J.; Hollings, S.; et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: A population-based study. Lancet Gastroenterol. Hepatol. 2021, 6, 199–208. [CrossRef]

18. Spencer, K.; Jones, C.M.; Girdler, R.; Roe, C.; Sharpe, M.; Lawton, S.; Miller, L.; Lewis, P.; Evans, M.; Sebag-Montefiore, D.; et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: A population-based study. Lancet Oncol. 2021, 22, 309–320. [CrossRef]

19. Amador, M.; Matias-Guiu, X.; Sancho-Pardo, G.; Martinez, J.C.; de la Torre-Montero, J.; Saiz, A.P.; Garrido, P.; Rodriguez-Lescure, A.; Paz-Ares, L. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open 2021, 6, 100157. [CrossRef]

20. Sud, A.; Torr, B.; Jones, M.; Broglio, J.; Scott, S.; Loveday, C.; Garrett, A.; Grahoud, F.; Nicol, D.L.; Jianji, S.; et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: A modelling study. Lancet Oncol. 2020, 21, 1035–1044. [CrossRef]

21. Maringe, C.; Spicer, J.; Morris, M.; Purushotham, A.; Nolte, E.; Sullivan, R.; Rachet, B.; Aggarwal, A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: A national, population-based, modelling study. Lancet Oncol. 2020, 21, 1023–1034. [CrossRef]

22. Urda, D.; Ribelles, N.; Subirats, J.; Franco, L.; Alba, E.; Jerez, J. Addressing critical issues in the development of an Oncology Information System. Int. J. Med Informatics 2013, 82, 398–407. [CrossRef] [PubMed]

23. Consejería de Salud y Familias. Junta de Andalucía. Available online: https://www.juntadeandalucia.es/institutodeestadistica/ycartografia/salud/static/index.html5 (accessed on 27 April 2021).

24. Greenwood, E.; Swanton, C. Consequences of COVID-19 for cancer care—A CRUK perspective. Nat. Rev. Clin. Oncol. 2021, 18, 3–4. [CrossRef] [PubMed]

25. Nyante, S.J.; Benefield, T.S.; Kuzmiak, C.M.; Earnhardt, K.; Pritchard, M.; Henderson, L.M. Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures. Cancer 2021, 127, 2111–2121. [CrossRef]

26. Te Maravel, L.; Wolfe, R.; McArthur, G.; Blake, L.A.; Evans, S.M. Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria. Med. J. Aust. 2021, 214, 281–283. [CrossRef] [PubMed]